Drugs / rAAV2/4.hRPE65
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01496040 | Sep 2011 → Aug 2014 | Leber congenital amaurosis | Nantes University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAAV2/4.hRPE65 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01496040 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Clinical Gene Therapy Protocol” NCT01496040 ↗ |
| Route | Other | “single subretinal injection” NCT01496040 ↗ |